Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial. Li Y, Li C, Zhao X, Li Y, et al. Oncologist 2025;30:oyae336.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li Y, Li C, Zhao X, Li Y, et al. Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial. Oncologist 2025;30:oyae336.
PMID: 40088185